Literature DB >> 27164054

Diastereo- and Enantioselective Construction of the Hexahydrocoumarin Scaffold via an Organocatalytic Asymmetric [3 + 3] Cyclization.

Xue Yang1, Yu-Chen Zhang1, Qiu-Ning Zhu1, Man-Su Tu1, Feng Shi1.   

Abstract

The first catalytic asymmetric construction of the biologically important hexahydrocoumarin scaffold has been established, which takes advantage of chiral thiourea-tertiary amine-catalyzed enantioselective transformations. Besides, this reaction also realized the first catalytic asymmetric [3 + 3] cyclization of 4-arylidene-2-aryloxazol-5(4H)-ones with cyclohexane-1,3-diones, which afforded structurally diverse 3-aminohexahydrocoumarin derivatives in excellent diastereoselectivities and high enantioselectivities (all >95:5 dr, up to 96:4 er). The investigation on the activation mode suggested that the chiral thiourea-tertiary amine catalyst simultaneously activated the two substrates via hydrogen-bonding interaction. Moreover, this reaction could be applied to a large scale synthesis of enantioenriched hexahydrocoumarin. This approach will not only provide an efficient method for the construction of the chiral hexahydrocoumarin scaffold but also enrich the research areas of asymmetric organocatalysis and catalytic enantioselective [3 + 3] cyclizations.

Entities:  

Year:  2016        PMID: 27164054     DOI: 10.1021/acs.joc.6b00603

Source DB:  PubMed          Journal:  J Org Chem        ISSN: 0022-3263            Impact factor:   4.354


  2 in total

1.  Stereoselective synthesis of chromane derivatives via a domino reaction catalyzed by modularly designed organocatalysts.

Authors:  Satish Jakkampudi; Ramarao Parella; John C-G Zhao
Journal:  Org Biomol Chem       Date:  2018-12-19       Impact factor: 3.876

2.  Syntheses of Highly Functionalized Spirocyclohexenes by Formal [4+2] Annulation of Arylidene Azlactones with Allenoates.

Authors:  Andreas Eitzinger; Katharina Zielke; Michael Widhalm; Raphaël Robiette; Mario Waser
Journal:  Asian J Org Chem       Date:  2018-05-04       Impact factor: 3.319

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.